Varaico: Literature-Extracted Genetic Variants

Gene:ALAS2
Variant:p.R559H
Back to variants list

ALAS2

NM_000032.5:p.R559H

Associated Papers

The role of genetic testing in accurate diagnosis of X-linked sideroblastic anemia: novel ALAS2 mutations and the impact of X-chromosome inactivation.

Jové-Solavera D et al.

Scientific Reports, 2025

40195342 (PubMed )
Supplement: 41598_2025_95590_MOESM1_ESM.pdf

Case report: A novel 11-bp deletion in exon 11 causing a frameshift in the C-terminal of the ALAS2 gene leading to X-linked sideroblastic anemia-a family study.

Al Kindi S et al.

Frontiers in Medicine, 2024

Structural basis for dysregulation of aminolevulinic acid synthase in human disease.

Taylor JL et al.

The Journal of Biological Chemistry, 2022

Human aminolevulinate synthase structure reveals a eukaryotic-specific autoinhibitory loop regulating substrate binding and product release.

Bailey HJ et al.

Nature Communications, 2020

32499479 (PubMed )
Supplement: 41467_2020_16586_MOESM1_ESM.docx

Molecular expression, characterization and mechanism of ALAS2 gain-of-function mutants.

Tchaikovskii V et al.

Molecular Medicine (cambridge, Mass.), 2019

Loss-of-function ferrochelatase and gain-of-function erythroid-specific 5-aminolevulinate synthase mutations causing erythropoietic protoporphyria and x-linked protoporphyria in North American patients reveal novel mutations and a high prevalence of X-linked protoporphyria.

Balwani M et al.

Molecular Medicine (cambridge, Mass.), 2013

Molecular and functional analysis of the C-terminal region of human erythroid-specific 5-aminolevulinic synthase associated with X-linked dominant protoporphyria (XLDPP).

Ducamp S et al.

Human Molecular Genetics, 2013

X-linked sideroblastic anemia due to carboxyl-terminal ALAS2 mutations that cause loss of binding to the β-subunit of succinyl-CoA synthetase (SUCLA2).

Bishop DF et al.

The Journal of Biological Chemistry, 2012

The carboxyl-terminal region of erythroid-specific 5-aminolevulinate synthase acts as an intrinsic modifier for its catalytic activity and protein stability.

Kadirvel S et al.

Experimental Hematology, 2012

ALAS2 acts as a modifier gene in patients with congenital erythropoietic porphyria.

To-Figueras J et al.

Blood, 2011

Hereditary sideroblastic anemia: pathophysiology and gene mutations.

Harigae H et al.

International Journal of Hematology, 2010

Select a paper to view details
UCSC Genome Browser·Imprint·Privacy·Terms·Feedback·Email Updates·

Regarding the variants extracted from papers and shown text snippets from research papers, the following holds: "Some rights reserved. This work permits non-commercial use, distribution and reproduction in any medium, provided the original author and source are credited."